Author

U. Oppermann

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 6 Biochemistry· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 8 Organism:human· 8 Assay:bulk RNA-seq· 3 Research Focus:cancer & tumor microenvironment· 3 Research Focus:cell type annotation· 2 Assay:ChIP-seq· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2

Frequent Co-Authors

M. Philpott· 4 shared A. P. Cribbs· 3 shared A. Cingoz· 2 shared D. Ahern· 2 shared E. Yilmaz· 2 shared F. Liu· 2 shared J. Dunford· 2 shared S. Pauklin· 2 shared

Activity by Year

2018-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

M. Philpott

Mutual co-authors in cluster

Author profile →

8 papers

Recent·Most cited

Chromatin-focused genetic and chemical screens identify BRPF1 as a targetable vulnerability in Taxol-resistant triple-negative breast cancer

O. Yedier-Bayram, A. Cingoz, E. Yilmaz, A. C. Aksu, B. Esin, N. Pinarbasi Degirmenci, A. D. Cavga, B. Dedeoglu, B. Cevatemre, H. Syed, M. Philpott, A. P. Cribbs, U. Oppermann, N. Lack, C. ACILAN AYHAN, , T. Bagci-Onder

The paper identifies BRPF1 as a key regulator of Taxol resistance in TNBC through genetic and chemical screens, showing its inhibition sensitizes resistant cells to chemotherapy.

bioRxiv · Apr 16, 2024Cancer Biology

High-dimensional mass cytometry reveals stemness state heterogeneity in pancreatic ductal adenocarcinoma

E. H. Ervin, D. Ahern, F. Liu, A. Rendek, Z. Soonawalla, U. Oppermann, P. Hulley, S. Pauklin

The paper uses mass cytometry to analyze stemness states in PDAC, revealing molecular heterogeneity and identifying a subset with plastic phenotypes.

bioRxiv · Feb 27, 2024 · PreprintCancer Biology

BRD9-SMAD2/3 orchestrates stemness and tumorigenesis in pancreatic ductal adenocarcinoma

Y. Feng, L. Cai, M. Pook, F. Liu, C.-H. Chang, M. A. Mouti, R. Nibhani, S. Wu, S. Deng, S. Militi, J. Dunford, M. Philpott, Y. Fan, G.-C. Fan, Q. Liu, , S. Pauklin

This study identifies BRD9 as a key regulator of pancreatic cancer stem cell stemness and tumorigenesis, showing that its inhibition reduces CSC self-renewal and enhances chemotherapy response.

bioRxiv · Mar 2, 2023Cancer Biology

HSD3B1 is an Oxysterol 3β-Hydroxysteroid Dehydrogenase in Human Placenta

A. Dickson, E. Yutuc, C. A. Thornton, J. E. Dunford, U. Oppermann, Y. Wang, W. J. Griffiths

The paper identifies HSD3B1 as an enzyme in human placenta that converts oxysterols into 3-oxo-4-ene derivatives, which are found in umbilical cord and maternal plasma.

bioRxiv · Apr 1, 2022Biochemistry

Orthogonal targeting of KDM6A/B and HDACs mediates potent therapeutic effects in IDH1-mutant glioma

A. Kayabolen, E. Yilmaz, G. N. Sahin, F. Seker-Polat, A. Cingoz, B. Isik, S. Acar, S. Karahuseyinoglu, H. Wakimoto, D. P. Cahill, I. Solaroglu, A. P. Cribbs, U. Oppermann, T. Bagci-Onder

This study identifies GSK-J4 and Belinostat as effective therapies for IDH1-mutant glioma by targeting KDM6A/B and HDACs, showing synergistic effects in vitro and in vivo.

bioRxiv · Nov 26, 2020 · PreprintCancer Biology

KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas

J. A. Heward, L. Koniali, A. D'Avola, K. Close, A. Yeomans, M. Philpott, J. Dunford, T. Rahim, A. F. Al Seraihi, J. Wang, K. Korfi, S. Araf, S. Iqbal, F. Bewicke-Copley, E. Kumar, , J. Fitzgibbon

This study shows that inhibiting KDM5 demethylases restores H3K4 methylation and reactivates genes in KMT2D mutant lymphomas, offering a potential therapeutic strategy.

bioRxiv · Jun 30, 2020Cancer Biology

Histone H3K27me3 demethylases regulate human Th17 cell development and effector functions by impacting on metabolism

A. P. Cribbs, S. Terlecki-Zaniewicz, M. Philpott, J. Baardman, D. Ahern, M. Lindow, S. Obad, H. Oerum, B. Sampey, P. Mander, H. Penn, P. Wordsworth, P. Bowness, R. K. Prinjha, M. de Winther, , U. Oppermann

This study identifies KDM6A and KDM6B as regulators of human Th17 cell development and effector functions by affecting metabolism and cytokine production.

bioRxiv · Oct 30, 2019Immunology

Epigenetic inactivation of oncogenic brachyury (TBXT) by H3K27 histone demethylase controls chordoma cell survival

L. Cottone, E. S. Hookway, A. Cribbs, G. Wells, P. Lombard, L. Ligammari, A. Tumber, R. Tirabosco, F. Amary, T. Szommer, C. Johannson, P. E. Brennan, N. Pillay, U. Oppermann, A. M. Flanagan

This study shows that inhibiting H3K27 demethylases reduces TBXT expression and kills chordoma cells by altering epigenetic marks and gene expression.

bioRxiv · Oct 1, 2018 · PreprintCancer Biology